Cailes J, Winter S, du Bois R M, Evans T W
Department of Thoracic Medicine, Royal Brompton Hospital, London, UK.
Chest. 1998 Jul;114(1):178-84. doi: 10.1378/chest.114.1.178.
Obliterative pulmonary vascular disease manifested clinically as pulmonary hypertension (PHT) may complicate systemic sclerosis (SSc). The aim of this study was to investigate possible endothelial dysfunction in patients with SSC complicated by PHT.
Prospective, randomized trial.
Postgraduate teaching hospital.
Patients having SSc with PHT (SSc-PHT) and SSc without PHT (SSc), confirmed using Doppler echocardiography, and normal individuals (control subjects).
I.v. infusion of the endothelially dependent vasodilator, substance P (maximum dose, 100 pmol/min), and the nonendothelially dependent vasodilator, adenosine (maximum dose, 0.05 mg/kg/min).
Effective pulmonary capillary blood flow (cardiac output minus right-to-left shunt) was measured in inert gas rebreathing, and calculated stroke index (SI) was used to reflect changes in pulmonary vascular resistance. During adenosine infusion, patients with SSc-PHT (n=5; mean age, 53+/-18 years) displayed a 25+/-16% increase in SI (p<0.05 compared with baseline), but no significant changes in SI were detected in the SSc (n=7; 54+/-6 years) or control (n=5; 35+/-5 years) groups. During infusion of substance P, SI rose by 32+/-18% in the control group at the maximum dose (p<0.05), but no change was observed in the SSc group. However, a fall in SI of -6+/-7% was detected in patients with SSc-PHT (p<0.05).
Substance P-mediated pulmonary vasodilation is absent in patients with systemic sclerosis, suggesting that endothelial dysfunction occurs early in the course of the illness, but some responsiveness to adenosine remains.
临床上表现为肺动脉高压(PHT)的闭塞性肺血管疾病可能是系统性硬化症(SSc)的并发症。本研究的目的是调查合并PHT的SSc患者可能存在的内皮功能障碍。
前瞻性随机试验。
研究生教学医院。
经多普勒超声心动图确诊的合并PHT的SSc(SSc-PHT)患者、不合并PHT的SSc(SSc)患者以及正常个体(对照组)。
静脉输注内皮依赖性血管扩张剂P物质(最大剂量,100 pmol/分钟)和非内皮依赖性血管扩张剂腺苷(最大剂量,0.05 mg/kg/分钟)。
在惰性气体再呼吸过程中测量有效肺毛细血管血流量(心输出量减去右向左分流),并使用计算得出的每搏输出指数(SI)来反映肺血管阻力的变化。在输注腺苷期间,SSc-PHT患者(n = 5;平均年龄,53±18岁)的SI增加了25±16%(与基线相比,p<0.05),但SSc组(n = 7;54±6岁)或对照组(n = 5;35±5岁)的SI未检测到显著变化。在输注P物质期间,对照组在最大剂量时SI升高了32±18%(p<0.05),但SSc组未观察到变化。然而,SSc-PHT患者的SI下降了-6±7%(p<0.05)。
系统性硬化症患者不存在P物质介导的肺血管舒张,这表明内皮功能障碍在疾病过程中早期就已发生,但对腺苷仍有一定反应性。